Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib versus placebo for advanced gastro-oesophageal cancer after at least 2 prior lines
ACTRN12616000420448Phase 3Completed
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in gastro-oesophageal junction cancer (GOJ) comparing Regorafenib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Nov 2016; status: completed.
02
Drugs
regorafenib
03
Conditions
gastro-oesophageal junction cancer (GOJ)
Beyond the preview
Go deeper on ACTRN12616000420448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000420448.